Patent in process
An innovative biopolymer obtained from a marine bacterium of the genus Pseudoalteromonas with tissue-regenerative properties. Its composition is analogous to the sugars (glycosaminoglycans, GAGs) naturally present in skin and joints, such as hyaluronic acid or chondroitin sulfate.
An active ingredient obtained from the sugars surrounding a marine bacterium isolated from deep-ocean environments, showing a composition and bioactivities similar to human glycosaminoglycans.
This bacterially derived biopolymer shows multiple bioactivities that support tissue regeneration:
Anti-elastase and anti-hyaluronidase activity.
Stimulates fibroblast proliferation and migration.
Promotes the secretion of procollagen, collagen and elastin.
Anti-inflammatory activity.
Excellent biocompatibility and rheological properties, acting as an emulsifier and thickener.
Glycosaminoglycans (GAGs) such as hyaluronic acid and chondroitin sulfate are widely used in cosmetics, medicine and nutrition. However, they are typically sourced from by-products of the meat and seafood industries, raising significant environmental, health, ethical and religious concerns.
This biopolymer provides a sustainable, animal-free alternative with structural and functional properties comparable to animal-derived GAGs. This innovation is especially relevant in the context of population ageing and the rising incidence of degenerative diseases, which are expected to significantly increase demand for GAGs in biomedical and nutraceutical applications.
Active ingredient for natural cosmetic products and regenerative medicine.
Sectors: Innovation management
Research lines: Bioeconomy, Biotechnology, Blue Economy
Research sublines: Blue biotechnology